Can a patient take Vicodin (hydrocodone and acetaminophen) while having COVID-19?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 19, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Can a Patient Take Vicodin While Having COVID-19?

Yes, a patient can take Vicodin (hydrocodone/acetaminophen) for pain management during COVID-19, but acetaminophen alone is preferred as first-line therapy, and the opioid component requires careful monitoring for drug interactions if the patient is receiving certain COVID-19 treatments. 1

Acetaminophen Component - Safe and Preferred

  • Acetaminophen (paracetamol) is the recommended first-line antipyretic and analgesic for COVID-19 patients with fever and pain, making the acetaminophen component of Vicodin appropriate. 1

  • Use acetaminophen for fever control when temperature exceeds 38.5°C, and it can be safely used for pain management in COVID-19 patients. 1

  • Acetaminophen has no significant drug interactions with COVID-19 therapies including lopinavir/ritonavir, remdesivir, hydroxychloroquine, tocilizumab, or interferon beta. 1

  • The maximum daily dose should not exceed 4 grams in 24 hours to avoid hepatotoxicity, which is particularly important since COVID-19 itself can cause liver injury in 14.8% to 53% of patients. 2

Hydrocodone (Opioid) Component - Use With Caution

  • If the patient is receiving lopinavir/ritonavir for COVID-19 treatment, opioid metabolism may be significantly affected, requiring dose adjustments or enhanced monitoring. 1

  • Morphine exposure decreases when used with lopinavir/ritonavir, while oxycodone exposure increases by 160%, suggesting that hydrocodone metabolism could similarly be altered. 1

  • Avoid using opioid medications in opioid-naive patients during COVID-19 due to increased psychological stress that may elevate requirements and risk of use for non-pain conditions like anxiety, depression, and insomnia. 1

Liver Function Monitoring is Critical

  • Patients with COVID-19 should have liver function tests monitored, especially when using potentially hepatotoxic medications or if they have pre-existing liver disease. 3

  • Monitor liver tests twice weekly in patients on potentially hepatotoxic medication or those with pre-existing liver disease. 3

  • If liver injury develops (ALT/AST elevation), consider whether it is due to COVID-19 itself, drug-induced liver injury from COVID-19 treatments, or the acetaminophen component of Vicodin. 3, 2

  • Off-label COVID-19 treatment should be withheld in cases of moderate-to-severe (category 2-3) liver injury, which may influence the decision to continue Vicodin. 3

Practical Recommendations

  • For mild to moderate COVID-19 pain, consider acetaminophen alone (without the opioid component) as the safer first-line option. 1, 4

  • If Vicodin is necessary for adequate pain control, use the lowest effective dose and shortest duration possible. 1

  • Document all medications the patient is receiving for COVID-19 treatment to assess for potential drug-drug interactions with hydrocodone. 1

  • Implement safe opioid prescribing procedures including monitoring for signs of respiratory depression, especially in patients with COVID-19 respiratory symptoms. 1

Common Pitfalls to Avoid

  • Do not exceed maximum daily acetaminophen doses (4 grams/24 hours) when combining Vicodin with other acetaminophen-containing products. 1

  • Do not assume all analgesics are contraindicated in COVID-19; acetaminophen is specifically recommended and safe. 1, 4

  • Do not ignore potential opioid-related drug interactions if the patient is on lopinavir/ritonavir or other protease inhibitors for COVID-19 treatment. 1

  • Avoid relying solely on pharmacological management without addressing the underlying cause of pain and monitoring for COVID-19 progression. 5

References

Guideline

Symptomatic Treatment for COVID-19 Patients

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Post-COVID Myalgia Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.